

1 Electromagnetic waves destabilize the SARS-CoV-2 Spike protein and reduce SARS-CoV-2
2 Virus-Like Particle (SC2-VLP) infectivity

3 Skyler Granatir^{b,*}, Francisco M. Acosta^{a,*}, Christina Pantoja^{a,*}, Johann Tailor^a, Angus Fuori^a, Bill
4 Dower^b, Henry Marr^b and Peter W. Ramirez^{a,#}

5 ^aDepartment of Biological Sciences, California State University Long Beach, Long Beach, CA.

6 ^bEpirus Inc., Torrance, California, USA.

7 Running Head: Electromagnetic waves decrease SC2-VLP infectivity

⁸ *: These authors contributed equally to this work.

9 #Address correspondence to Peter Ramirez (Peter.Ramirez@csulb.edu)

10

11

12 Abstract

13 Infection and transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
14 CoV-2) continues to pose a global public health concern. Using electromagnetic waves
15 represents an alternative strategy to inactivate pathogenic viruses such as SARS-CoV-2 and
16 reduce overall transmission. However, whether electromagnetic waves reduce SARS-CoV-2
17 infectivity is unclear. Here, we adapted a coplanar waveguide (CPW) to identify electromagnetic
18 waves that could neutralize SARS-CoV-2 virus-like particles (SC2-VLPs). Treatment of SC2-
19 VLPs, particularly at frequencies between 2.5-3.5 GHz at an electric field of 400 V/m for 2 minutes,
20 reduced infectivity. Exposure to a frequency of 3.1 GHz decreased the binding of SC2-VLPs to
21 antibodies directed against the Spike S1 subunit receptor binding domain (RBD). These results
22 suggest that electromagnetic waves alter the conformation of Spike, thereby reducing viral
23 attachment to host cell receptors. Overall, this data provides proof-of-concept in using
24 electromagnetic waves for sanitation and prevention efforts to curb the transmission of SARS-
25 CoV-2 and potentially other pathogenic enveloped viruses.

26 **Keywords:** SARS-CoV-2, Spike, Electromagnetic Waves, Coplanar Waveguide, Transmission,
27 Sanitation

28

29 **Introduction**

30 Coronaviruses consist of a family of enveloped positive-sense single-stranded RNA
31 viruses that infect a wide variety of mammals and can cause mild or severe disease¹. Three
32 human coronaviruses emerged in the 21st century that pose a significant threat to public health:
33 severe acute respiratory syndrome coronavirus 1 (SARS or SARS-CoV-1), middle east
34 respiratory syndrome (MERS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
35 2)²⁻⁵. SARS-CoV-2 is the causative agent of the COVID-19 pandemic⁶. Viral transmission of
36 human coronaviruses occurs via person-to-person contact, respiratory droplets, and through
37 touching contaminated surfaces⁷. As of August 2024, SARS-CoV-2 has infected nearly 800
38 million individuals and led to over 7 million deaths (WHO). Despite effective vaccines⁸ and
39 therapeutics^{9,10}, SARS-CoV-2 continues to circulate and can lead to complications, particularly in
40 high-risk groups. Therefore, increased strategies to curb SARS-CoV-2 transmission are needed.

41 Standard pathogen disinfection includes the use of high temperatures, ultraviolet and
42 ionizing radiation, and chemical agents, though these techniques have limitations¹¹⁻¹⁵.
43 Electromagnetic waves offer an alternative strategy to inactivate viruses, possessing high
44 penetration, uniform heating, and minimal pollution¹⁶. How electromagnetic waves alter virus
45 infectivity is an active area of investigation, though it can include changes in virus morphology^{15,17},
46 damage to viral RNA¹⁸ and denaturation of enveloped virus glycoproteins¹⁹.

47 The SARS-CoV-2 Spike glycoprotein mediates attachment and entry into host cells. Spike
48 contains S1 and S2 subunits that exist in a glycosylated trimeric form on the surface of a mature
49 virus. The receptor binding domain (RBD) within the Spike S1 subunit facilitates binding to host
50 cell receptors such as ACE2⁵. A polybasic furin cleavage site is present at the junction between
51 the S1 and S2 subunits²⁰. The host protein furin cleaves Spike, exposing an S2' cleavage site
52 within the S2 domain. Cleavage by the host serine protease TMPRSS2 exposes the S2 fusion
53 peptide (FP), which inserts into the host cell membrane to mediate entry at the cell surface^{21,22}.

54 In some cases, SARS-CoV-2 entry can occur via endocytosis whereby Spike cleavage occurs in
55 a pH-dependent manner mediated by the cysteine protease cathepsin L²³.

56 The goal of this study was to determine whether electromagnetic waves could affect the
57 infectivity of SARS-CoV-2. For our studies, we adapted a system using SARS-CoV-2 virus-like
58 particles (SC2-VLPs) that package and deliver exogenous RNA transcripts (i.e. luciferase) into
59 target cells²⁴. Because SC2-VLPs contain each of the SARS-CoV-2 structural proteins (Spike,
60 Envelope, Matrix and Nucleocapsid), they recapitulate authentic aspects of SARS-CoV-2 entry,
61 assembly and release and are suitable to work with in a Biosafety Level 2 (BSL2) setting. We
62 employed a coplanar waveguide (CPW) to determine the absorption spectrum of SC2-VLPs. We
63 then tested a range of frequencies to determine whether they have any effect on reducing SC2-
64 VLP infectivity. We found that frequencies within 2.5-3.5 GHz reduced infectivity when exposing
65 SC2-VLPs to an electric field of 400 V/m for 2 minutes (180 W input supply to TEM cell). This
66 correlated with reduced binding of antibodies to Spike targeting the S1 RBD, suggesting that
67 electromagnetic waves can induce conformational changes within Spike that negatively impact
68 viral attachment/entry into host cells. To our knowledge, our data is the first to provide direct
69 experimental evidence of using electromagnetic waves to reduce SARS-CoV-2 infectivity and
70 provide a plausible mechanism for how this occurs. This study serves as a proof-of-concept for
71 further development in using electromagnetic waves to combat COVID-19 transmission.

72

73 **Results**

74 *Identification of electromagnetic wave frequencies absorbed by SC2-VLPs using a Coplanar
75 Waveguide (CPW)*

76 To explore the permittivity of SC2-VLPs at a range of frequencies, we employed a coplanar
77 waveguide (CPW) in combination with a Vector Network Analyzer (VNA). We modeled our design
78 after Yang et al, who designed a CPW circuit to measure the electromagnetic wave absorption
79 spectra of H3N2 influenza viruses²⁵. A CPW is a waveguide in which all conductors supporting

80 wave propagation is placed on the same plane. Active components can be placed along a
81 microstrip (Figure 2A). Each end of the CPW is connected to a VNA, which can emit and receive
82 thousands of frequency points over a short interval of time (Figure 2B). In this manner, the
83 absorption of any fluid along the microstrip can be determined. A higher absorption implies a
84 greater electromagnetic wave permittivity at a given frequency. This can lead to changes in virus
85 architecture, rendering them non-infectious. To obtain an absorption spectrum for SC2-VLPs, we
86 dripped them uniformly along our CPW microstrip (Figure 2A). We observed local peaks around
87 3.1 GHz and 6 GHz (Figure 2C). It should be noted that even without buffer on the CPW, we had
88 previously observed resonance around 5-6 GHz, likely due to half-wavelength resonance, i.e.
89 half-wavelength would geometrically fit across the CPW at these frequencies and produce a
90 trapped standing wave. Nonetheless, when attempting to remove those contributions, we still
91 witnessed significant absorption by SC2-VLPs at the higher frequencies.

92 *Electromagnetic waves reduce SARS-CoV-2 Virus Like Particle (SC2-VLP) infectivity*

93 Next, we determined whether exposing SC2-VLPs to a range of electromagnetic
94 frequencies could affect their infectivity (Figure 3A). We chose the following frequencies based
95 on our absorption spectra (Figure 2C): 1.0-2.5 GHz, 2-5-3.5 GHz, 3.5-4.8 GHz, and 4.8-6 GHz.
96 We also treated SC2-VLPs with 2.45 GHz using Microwave (MW) radiation as a control. Overall,
97 treatment of SC2-VLPs with either electromagnetic waves or MW irradiation reduced infectivity
98 relative to untreated samples (Figure 3C). We observed a statistically significant reduction in
99 infectivity when SC2-VLPs were treated with electromagnetic waves within the 2.5-3.5 GHz and
100 3.5-4.8 GHz range (Figure 3B). We next sought to determine the mechanism for how EMPs
101 reduced SC2-VLP infectivity.

102 *Electromagnetic waves destabilize the SARS-CoV-2 Spike Receptor Binding Domain (RBD)*

103 Using molecular simulations, applying electric fields induced a conformational change
104 within the recognition loop L3 of the Spike receptor binding domain (RBD), changing two parallel
105 beta sheets into an unstructured coil that diminished binding to ACE2²⁶. In another study, applying

106 a 2.45 GHz electromagnetic wave denatured the SARS-CoV-2 Spike S1 subunit *in vitro*¹⁹.
107 Therefore, we asked whether SC2-VLPs treated with electromagnetic waves led to destabilization
108 of SARS-CoV-2 Spike. We tested this by measuring the ability of untreated or electromagnetic
109 wave treated SC2-VLPs to bind an antibody targeting the Spike S1 receptor binding domain
110 (S1RBD) via Enzyme-Linked Immunosorbent Assay (ELISA) (Figure 4A). We tested
111 electromagnetic wave frequencies that led to either the greatest (3.1 GHz) or smallest (5.9 GHz)
112 reduction in infectivity (Figure 3B). Interestingly, SC2-VLPs treated with 3.1 GHz or 5.9 GHz
113 reduced SARS-CoV-2 Spike binding by approximately 70% and 15%, respectively (Figure 4B).
114 Overall, this data supports a model whereby electric fields alter the conformation of Spike,
115 negatively impacting its ability to bind ACE2 and enter cells.

116

117 **Discussion**

118 This study sought to determine the role of using electromagnetic waves to inactivate
119 enveloped viruses, particularly SARS-CoV-2. We present the first proof-of-concept study showing
120 that nonthermal electromagnetic waves of 2.5-3.5 GHz at 400 V/m for 2 minutes alter the
121 conformation of the SARS-CoV-2 Spike S1 RBD, reducing the infectivity of SC2-VLPs.

122 Mechanistically, inactivation of viruses using electromagnetic waves can occur due to
123 thermal, nonthermal, or physical resonance effects. Thermal effects inactivate viruses by
124 increasing the surrounding temperature. Exposing human coronavirus 229E to electromagnetic
125 waves of 95 GHz at a power density of 70-100 W/cm² for 2 seconds led to virus inactivation
126 induced by a 100° C change in temperature¹⁵. This resulted in drastic changes to virus
127 morphology, forming holes in the envelope of 229E virions revealed by scanning electron
128 microscopy (SEM)¹⁵. Siddharta et. al. reduced or completely inactivated Human
129 Immunodeficiency Virus (HIV-1) and Hepatitis C Virus (HCV) using electromagnetic waves at a
130 frequency of 2450 GHz and power densities between 360W – 800W²⁷. HIV-1 and HCV
131 inactivation were dependent on the cell culture medium temperature rising from 26° C to 92° C,

132 as no apparent changes in viral infectivity were recorded when the temperature was held constant
133 due to viruses being subjected to either low power (90 or 180 W; 3 minutes) or short-burst high
134 power (600 W or 800 W; 1 minute) electromagnetic waves²⁷. A recent study reported a 9.375 GHz
135 frequency at 100 mW/cm² inactivated coronavirus mouse hepatitis A 59 (MHV-A59) by physical
136 destruction of the viral envelope and genome²⁸. However, whether these phenomena occurred
137 due to changes in thermal or physical resonance effects were not explored. Here, we did not
138 detect any changes in temperature when subjecting SC2-VLPs to various electromagnetic
139 frequencies (data not shown), suggesting our results occur in a nonthermal manner.

140 Physical resonance effects occur when objects absorb more energy from their surrounding
141 environment when vibrating at their natural frequency and wavelength. Viruses resonate in the
142 confined-acoustic dipolar mode with electromagnetic waves of the same frequency^{16,25}. This leads
143 to a structure resonance energy transfer (SRET) from electromagnetic waves to confined acoustic
144 vibrations (CAV) in viruses, inducing fracture of the virus structure. Indeed, inactivation of
145 influenza A virus strain H3N2 occurred when exposing the virus to a frequency of 6 GHz at 486
146 W/m² power density, resulting in the physical rupture of the viral envelope through resonance
147 effects despite minimal increases in temperature²⁵. We did not directly test whether exposure of
148 SC2-VLPs to 2.5-3.5 GHz led to virus fracture or damaged viral protein(s)/genetic material.

149 Electromagnetic waves can cause molecules to rotate or vibrate in a nonthermal manner,
150 altering their polarity to induce changes in the conformation of viral proteins. A 2.45 GHz 700W
151 electromagnetic wave denatured the SARS-CoV-2 Spike S1 subunit by 95% in the absence of
152 heat¹⁹. Thus, conformational changes in Spike occurred due to pure electromagnetic effects.
153 Another study used molecular simulations to conclude that exposure to electric fields can alter
154 the conformation of SARS-CoV-2 Spike and its variants, negatively impacting its ability to bind to
155 ACE2²⁶. Interestingly, these simulations reported minimal structural damage to the Spike S2
156 subunit, suggesting Spike's susceptibility to electric fields is limited to its prefusion (S1 subunit),
157 rather than post fusion (S2 subunit) conformational state²⁹. Our data are suggestive of a

158 nonthermal model, since exposure of SC2-VLPs to distinct electromagnetic waves reduced the
159 binding of Spike to antibodies targeting the S1 RBD (Figure 4B). Future studies should directly
160 test whether the Spike S2 subunit, unlike S1, is relatively resistant to electric fields.

161 Our study has limitations. First, SC2-VLPs may not wholly reflect what occurs with SARS-
162 CoV-2. Because SARS-CoV-2 is classified as a BSL3 agent, we did not have the research
163 facilities to perform work with this pathogen. However, because SC2-VLPs mimic the viral
164 assembly, packaging, production, and delivery of exogenous transcripts, they provide important
165 insights into the mechanisms governing SARS-CoV-2 replication, including attachment and entry.
166 Nonetheless, future studies should address whether electromagnetic fields can reduce the
167 infectivity of authentic replication-competent SARS-CoV-2. Second, we did not determine whether
168 other SARS-CoV-2 Spike variants are susceptible to electromagnetic fields. Here, we created
169 SC2-VLPs using a plasmid expressing the SARS-CoV-2 Spike protein derived from the original
170 Wuhan-1 strain²⁴. Exposure to electric fields via molecular simulations induced structural changes
171 within the SARS-CoV-2 Spike RBDs from wildtype (Wuhan-1) as well as Alpha (B.1.1.7), Beta
172 (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1) variants^{26,29}. We hypothesize that
173 the structural damage induced by electric fields towards ancestral Spike will extend to other Spike
174 variants. However, this has yet to be experimentally tested. Finally, whether our CPW/VNA
175 system reduces the infectivity of IAV, HIV-1, HCV or other pathogenic enveloped viruses is
176 intriguing but was beyond the scope of this study.

177 In summary, electromagnetic waves offer an intriguing strategy to inactivate pathogenic
178 viruses. By using a unique CPW and VNA, we rapidly obtained the absorption spectrum of SC2-
179 VLPs, providing insightful information about the permittivity and susceptibility of SARS-CoV-2 to
180 certain electromagnetic wave frequencies. Identifying electromagnetic waves that have minimal
181 impacts on the human body may offer novel *in-vivo* methods for neutralizing pathogenic viruses.
182 Beyond inactivation, the CPW technique employed here could potentially be used to detect
183 viruses with *a priori* knowledge of the virus's absorption characteristics. Deployment of a portable

184 system utilizing a VNA-like circuit could measure absorption at the most informative frequencies
185 in a wide range of samples. Thus, electromagnetic waves provide several encouraging future
186 developments to improve viral detection, inactivation, and sanitation.

187 **Materials and Methods**

188 Hardware: The electronic system consisted of a transverse electromagnetic (TEM) cell, function
189 generator, signal generator, amplifier, and computer (Figure 1). The waveform originated from a
190 signal and function generator commanded by a computer which was interfaced with the
191 equipment to set parameters such as pulse width, input power, and frequency. After the signal
192 generator was triggered by the function generator, the signal was transmitted to a wideband
193 amplifier (AR500M6G), outputting a 180-250 W signal to the TEM cell through N-type cables. The
194 TEM cell used for our experimentation was a Tescom TC-5062C. This machine possessed a
195 shielded enclosure providing powerful electric fields (200 - 2000 V/m). An input power of 180 W,
196 corresponding to 413 V/m, was used for all experiments. Any leaked radiation was below 5
197 mV/cm², the FCC human safety threshold.

198 *Cell Lines and Plasmids*: HEK293T (ATCC; CRL-3216) were maintained in complete DMEM
199 (Thermo Fisher Scientific): 10% fetal bovine serum (FBS; Corning), glutamine (Thermo Fisher
200 Scientific) and 1% penicillin/streptomycin (Thermo Fisher Scientific). HEK293 cells expressing
201 human ACE2 and TMPRSS2 (Invivogen; hkb-hace2tpsa) were propagated in complete DMEM
202 supplemented with puromycin (0.5mg/ml), hygromycin B (200 mg/ml) and zeocin (100 mg/ml).
203 The following plasmids were gifts from Dr. Jennifer Doudna and purchased from Addgene: CoV-
204 2-N-WT-Hu1 (#177937), CoV-2-M-IRES-E (#177938), CoV-2-Spike-EF1a-D614G-N501Y
205 (#177939), Luc-noPS (#177940), and Luc-PS9 (#177942).

206

207 *Generation of SARS-CoV-2 Virus-Like Particles (SC2-VLPs)*: HEK293T cells (3.5×10^6 in 10 mL
208 total volume) were seeded in 10 cm dishes 24 hours prior to transfection. The next day, cells were

209 transfected with a total of 20 μ g plasmid DNA according to the following molar ratios: 1 CoV2-N-
210 WT-Hu1, 0.5 CoV-2-M-IRES-E , 0.5 Luc-PS9 or Luc-noPS and 0.0125 CoV2-Spike-EF1a-D614G-
211 N501Y. Plasmids were diluted in water to a final volume of 400 μ L, along with 100 μ L 2.5 M
212 calcium chloride (CaCl_2) and 500 μ L 2X Hepes Buffered Saline (HBS; pH 7.05). This transfection
213 mixture was vortexed, incubated for 1 minute at room temperature and added dropwise over the
214 entire culture dish. To increase transfection efficiency, 10 μ L of chloroquine (100 mM) was added
215 prior to returning cells to the incubator (37 °C; 5% CO_2). Media was changed 16-18 hours post
216 transfection. Forty-eight hours post transfection, supernatant (SC2-VLPs) was collected, clarified
217 by centrifugation, filtered (0.45 μ M PES), and stored at -80 °C.

218

219 *SC2-VLP infection and luciferase readout:* In a clear, sterile, 96-well round-bottom plate, 30,000
220 HEK293/ACE2/TMPRSS2 cells were either left untreated or mixed with 50 μ L SC2-VLPs in
221 triplicate. Cells and SC-VLPs were incubated (37 °C; 5% CO_2) overnight. The next day,
222 supernatant was removed, cells rinsed with 100 μ L 1X PBS (ThermoFisher) and lysed with 20 μ L
223 passive lysis buffer (Promega) for 15 minutes at room temperature with gentle rocking. The cells
224 were then transferred to an opaque white 96-well flat-bottom plate, mixed with 50 μ L reconstituted
225 luciferase assay buffer (Promega), and luciferase measured immediately on a plate reader (Biotek
226 Synergy H1). The data was expressed as Relative Light Units (RLU).

227

228 *Enzyme-Linked Immunosorbent Assay (ELISA):* All reagents, standards, and samples were
229 prepared according to the manufacturer's instructions (RayBiotech; Catalog #: ELV-COVID19S1).
230 Briefly, 100 μ L of diluted standard or sample (untreated or EMP-treated SC2-VLPs) was added
231 to a 96-well plate in duplicate and incubated for 2.5 hours. After incubation, wells were washed
232 and incubated with 100 μ L of 1X biotinylated antibody for 1 hour. Following washing, wells were
233 incubated with 100 μ L of 1X streptavidin solution for 45 minutes. After a final wash step, 100 μ L

234 of a TMB One-Step substrate reagent was added to each well for 30 minutes in the dark, followed
235 by the addition of 50 uL Stop Solution. Absorbance was read immediately at 450 nm on a plate
236 reader (Synergy H1). All incubation steps were carried out at room temperature.

237

238 *Data analysis and statistics:* Data were analyzed and compiled in Microsoft Excel and GraphPad
239 Prism 9.0 software. Statistical tests were performed in Graph Prism. Significance between
240 samples was assessed using either a Wilcoxon ranked sum test or Analysis of Variance (ANOVA).
241 P values are denoted on the figures. Figures were produced using Adobe Illustrator (CS5) and
242 BioRender software.

243

244 **References**

245 1. Kung, Y.-A. *et al.* Molecular Virology of SARS-CoV-2 and Related Coronaviruses. *Microbiol*
246 *Mol Biol Rev* **86**, e00026-21 (2022).

247 2. Kuiken, T. *et al.* Newly discovered coronavirus as the primary cause of severe acute
248 respiratory syndrome. *Lancet* **362**, 263–270 (2003).

249 3. Peiris, J. S. M. *et al.* Coronavirus as a possible cause of severe acute respiratory syndrome.
250 *Lancet* **361**, 1319–1325 (2003).

251 4. Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E. & Fouchier, R. A.
252 M. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. *N Engl J*
253 *Med* **367**, 1814–1820 (2012).

254 5. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat
255 origin. *Nature* **579**, 270–273 (2020).

256 6. Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J*
257 *Med* **382**, 727–733 (2020).

258 7. Wang, C. C. *et al.* Airborne transmission of respiratory viruses. *Science* **373**, eabd9149
259 (2021).

260 8. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J*
261 *Med* **383**, 2603–2615 (2020).

262 9. Owen, D. R. *et al.* An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of
263 COVID-19. *Science* **374**, 1586–1593 (2021).

264 10. Wen, W. *et al.* Efficacy and safety of three new oral antiviral treatment (molnupiravir,
265 fluvoxamine and Paxlovid) for COVID-19 : a meta-analysis. *Ann Med* **54**, 516–523 (2022).

266 11. Lytle, C. D. & Sagripanti, J.-L. Predicted Inactivation of Viruses of Relevance to Biodefense
267 by Solar Radiation. *J Virol* **79**, 14244–14252 (2005).

268 12. Feng, K., Divers, E., Ma, Y. & Li, J. Inactivation of a Human Norovirus Surrogate, Human
269 Norovirus Virus-Like Particles, and Vesicular Stomatitis Virus by Gamma Irradiation. *Appl
270 Environ Microbiol* **77**, 3507–3517 (2011).

271 13. Almeida, C. F., Purcell, D. F. J., Godfrey, D. I. & McAuley, J. L. The Efficacy of Common
272 Household Cleaning Agents for SARS-CoV-2 Infection Control. *Viruses* **14**, 715 (2022).

273 14. Ahmad Wadi, A. F. A. *et al.* Effects of Strain Differences, Humidity Changes, and Saliva
274 Contamination on the Inactivation of SARS-CoV-2 by Ion Irradiation. *Viruses* **16**, 520 (2024).

275 15. Kaczmarczyk, L. S. *et al.* Corona and polio viruses are sensitive to short pulses of W-band
276 gyrotron radiation. *Environ Chem Lett* **19**, 3967–3972 (2021).

277 16. Sun, C.-K. *et al.* Resonant Dipolar Coupling of Microwaves with Confined Acoustic Vibrations
278 in a Rod-shaped Virus. *Sci Rep* **7**, 4611 (2017).

279 17. Wu, Y. & Yao, M. In situ airborne virus inactivation by microwave irradiation. *Chin Sci Bull* **59**,
280 1438–1445 (2014).

281 18. Wu, Y. *et al.* MS2 virus inactivation by atmospheric-pressure cold plasma using different gas
282 carriers and power levels. *Appl Environ Microbiol* **81**, 996–1002 (2015).

283 19. Afaghi, P., Lapolla, M. A. & Ghandi, K. Denaturation of the SARS-CoV-2 spike protein under
284 non-thermal microwave radiation. *Sci Rep* **11**, 23373 (2021).

285 20. Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin
286 of SARS-CoV-2. *Nat Med* (2020) doi:10.1038/s41591-020-0820-9.

287 21. Hoffmann, M., Kleine-Weber, H. & Pöhlmann, S. A Multibasic Cleavage Site in the Spike
288 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* **78**, 779–
289 784.e5 (2020).

290 22. Ozono, S. *et al.* SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced
291 ACE2-binding affinity. *Nat Commun* **12**, 848 (2021).

292 23. Laporte, M. *et al.* The SARS-CoV-2 and other human coronavirus spike proteins are fine-
293 tuned towards temperature and proteases of the human airways. *PLoS Pathog* **17**, e1009500
294 (2021).

295 24. Syed, A. M. *et al.* Rapid assessment of SARS-CoV-2–evolved variants using virus-like
296 particles. *Science* **374**, 1626–1632 (2021).

297 25. Yang, S.-C. *et al.* Efficient Structure Resonance Energy Transfer from Microwaves to
298 Confined Acoustic Vibrations in Viruses. *Sci Rep* **5**, 18030 (2015).

299 26. Arbeitman, C. R., Rojas, P., Ojeda-May, P. & Garcia, M. E. The SARS-CoV-2 spike protein is
300 vulnerable to moderate electric fields. *Nat Commun* **12**, 5407 (2021).

301 27. Siddharta, A. *et al.* Inactivation of HCV and HIV by microwave: a novel approach for
302 prevention of virus transmission among people who inject drugs. *Sci Rep* **6**, 36619 (2016).

303 28. Xiao, Y. *et al.* Inactivation efficacy and mechanism of 9.375 GHz electromagnetic wave on
304 coronavirus. *Virology* **598**, 110165 (2024).

305 29. Lipskij, A., Arbeitman, C., Rojas, P., Ojeda-May, P. & Garcia, M. E. Dramatic Differences
306 between the Structural Susceptibility of the S1 Pre- and S2 Postfusion States of the SARS-
307 CoV-2 Spike Protein to External Electric Fields Revealed by Molecular Dynamics Simulations.
308 *Viruses* **15**, 2405 (2023).

309

310

311 **Acknowledgments**

312 We thank Dr. John Guatelli for review and insightful comments on the manuscript. This study was
313 supported, in part, by an NSF SBIR award (#: 2035140) to Epirus, Inc. PWR was supported, in
314 part, by a New Investigator Grant (GF00610932) from the California State University
315 Biotechnology program (CSUBIOTECH) and NIH award R16AI184450. C.P. was supported, in
316 part, by award T32GM138075 from the National Institutes of General Medical Sciences (NIGMS).

317 **Author Contributions**

318 Conceptualization: S.G., B.D., H.M., P.W.R.; Validation: F.M.A., C.P., S.G., P.W.R.; Methodology,
319 F.M.A., C.P., S.G., J.T., A.F., P.W.R.; Project Administration: P.W.R.; Writing – Original Draft,
320 S.G, F.M.A., P.W.R.; Writing – Review & Editing, S.G, F.M.A., C.P., P.W.R.; Supervision, P.W.R.;
321 Funding Acquisition: H.M., P.W.R.

322 **Competing Interests Statement**

323 The authors declare no competing interests.

324 **Figure Legends**

325 **Figure 1: Electromagnetic wave hardware setup.** A waveform originates from a signal and
326 function generator commanded by a computer. After the signal generator is triggered by the
327 function generator, the signal is transmitted to a wideband amplifier (AR500M6G). The amplifier
328 outputs 180 W signal to a transverse electromagnetic (TEM) cell through N-type cables.

329 **Figure 2: Coplanar Waveguide (CPW) setup and absorption spectra of SARS-CoV-2 Virus-
330 Like Particles (SC2-VLPs).** A.) Illustration of a virus suspended solvent on a CPW. B.) Epirus
331 CPW circuit. C.) SC2-VLP absorption spectra. RF: Radio-Frequency signal. DUT: Device-Under-
332 Test


333 **Figure 3: Electromagnetic waves reduce infectivity of SARS-CoV-2 Virus-Like Particles
334 (SC2-VLPs).** A.) Diagram of SC2-VLP production, electromagnetic wave treatment and infectivity
335 assay. Plasmids expressing each of the SARS-CoV-2 structural proteins (Nucleocapsid (N);
336 Matrix (M); Envelope (E); and Spike (S)), or a plasmid encoding a packaging signal and luciferase

337 transcript (Luc-PS9) were transfected into viral producer cells (HEK293T). SC2-VLPs were then
338 collected, left untreated or treated with various electromagnetic wave frequencies and used to
339 infect target cells (HEK293T-ACE2-TMPRSS2). The next day, luciferase was measured as a
340 readout of infectivity. Created in BioRender.com. B.) SC2-VLP infectivity assay. Data represent
341 mean +/- SD of 5 independent experiments performed in triplicate. P-values indicate Wilcoxon
342 matched-pair signed rank test of treated compared to untreated samples. (n= 90 (Untreated); n=
343 36 (1.0-2.5 GHz & 2.5-3.5 GHz) n = 15 (3.5-4.8 GHz), n = 33 (4.8-6 GHz), n = 18 (MW)). RLU:
344 Renilla Luciferase Units (RLU). MW: Microwave

345 **Figure 4: Electromagnetic waves destabilize the SARS-CoV-2 Spike protein.** A.) SC2-VLPs
346 were produced, collected, treated with select electromagnetic wave frequencies for 2 minutes,
347 and subjected to an ELISA to measure the stability of the Spike receptor binding domain (RBD).
348 Created in BioRender.com. B.) Spike (S1RBD) ELISA. Data represent +/- SD of 2 independent
349 experiments performed in quadruplicate, except for one condition (3.1 GHz) that was analyzed
350 once in quadruplicate and once in triplicate. P-values indicate one-way ANOVA tests of treated
351 compared to untreated samples.

352

Figure 1



A






Figure 2

B



C



A






Figure 3

B



A

Figure 4



B

